Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: Final results of a multicenter phase II study

Annals of Oncology

Volumn 13, Issue 1, 2002, Pages 103-107

  Monnet, I ^a   De Cremoux, H ^b   Soulie P ^c   Saltiel Voisin, S ^d   Bekradda, M ^e,f   Saltiel, J C ^d   Brain, E ^c   Rixe, O ^g   Yataghene, Y ^h   Misset, J L ^e   Cvitkovic, E ^e,f  

^a Centre Hospitalier Intercommunal   (France)

^b CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^c CENTRE RENÉ HUGUENIN   (France)

^d CENTRE HOSPITALIER   (France)

^e HÔPITAL PAUL BROUSSE   (France)

^f CAC   (France)

^g Department of Urology   (France)

^h SANOFI   (France)

Author keywords

Combination; Non small cell lung cancer; Oxaliplatin; Phase II; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; SEROTONIN AGONIST;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

EID: 20244364644     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf006     Document Type: Article

References (18)

1. Chemotherapy in non-small cell lung cancer
2. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
3. The role of new agents in advanced non-small-cell lung carcinoma
4. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
5. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
6. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
7. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small-cell lung cancer
8. New insights into the cost-effectiveness of lung cancer treatment
9. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
10. An economic analysis of Southwest Oncology Group Trial S9509: Cisplatin/vinorelbine vs. carboplatin/paclitaxel for advanced nonsmall cell lung cancer
11. Oxaliplatin: A review of preclinical and clinical studies
12. Association pour le Traitement des Tumeurs Intra Thoraciques (ATTIT). Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC)
13. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer
14. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump
15. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Italy Cooperative Oncology Group
16. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer
17. How to define the recommended dose based on the cumulative toxicity in combination Phase I studies: Example of the gemcitabine non-small-cell lung (NSCLC) and ovarian carcinoma (OC)
18. Phase I study of gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report